An open study of pamidronate in the treatment of refractory ankylosing spondylitis

Journal of Rheumatology

Volumn 25, Issue 4, 1998, Pages 714-717

  Maksymowych, Walter P ^a,b,c   Jhangri, Gian S ^a,c   Leclercq, Sharon ^a,c   Skeith, Ken ^a,c   Yan, Alex ^a,c   Russell, Anthony S ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ALBERTA ENVIRONMENT AND PARKS   (Canada)

^c Department of Medicine ^*

Author keywords

Ankylosing spondylitis; Inflammation; Pamidronate

Indexed keywords

PAMIDRONIC ACID;

ACUTE PHASE RESPONSE; ADULT; AGED; ANKYLOSING SPONDYLITIS; ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL ARTICLE; CRYSTAL STRUCTURE; DELAYED HYPERSENSITIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GROWTH INHIBITION; HUMAN; INFLAMMATION; MALE; OSTEOCLAST; PRIORITY JOURNAL;

EID: 0031899867     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Dougados M, van der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondyloarthropathy: a randomized multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
2. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
3. Pennanen N, Lapinjoki S, Urtti A, Monkkonen J. Effect of liposomal and free bisphosphonates on the IL-1β, IL-6, and TNFα secretion from RAW 264 cells in vitro. Pharm Res 1995;12:916-22.
4. Dunn CJ, Galinet LA, Wu H, et al. Demonstration of novel anti-arthritic and anti-inflammatory effects of diphosphonates. J Pharmacol Exp Ther 1993;266:1691-8.
5. Flora L. Comparative anti-inflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis Rheum 1979;22:340-6.
6. Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BAC, Breedveld FC. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 1994;21:2016-20.
7. Ralston SH, Hackling L, Willocks L, Bruce F, Pitkeathly DA. Clinical, biochemical, and radiographic effects of aminohydroxypropylidene biphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 1989;48:396-9.
8. Moll JMH, Wright V. New York clinical criteria for ankylosing spondylitis. Ann Rheum Dis 1973;32:354-63.
9. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
10. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
11. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
12. Epstein WV. Expectation bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experience. Arthritis Rheum 1996;39:1773-80.
13. Schweitzer DH, Oostendrop-Van de Ruit M, Van Der Pluijm G, Lowik CWGM, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1995;10:956-62.
14. Sansoni P, Passeri G, Fagnoni F, et al. Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 1995;10:1719-25.
15. Thomas BJ, Amstutz HC. Results of the administration of diphosphonate for the prevention of heterotopic ossification after total hip arthroplasty. J Bone Joint Surg 1985;67:400-3.
16. Cram RL, Barmada R, Geko WB, Ray RD. Diphosphonate treatment of calcinosis universalis. N Engl J Med 1971;285:1012-3.